Sensei Bio

Today, Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics. ... 1/7

Read more about the acquisition in the press release linked in the comments. 7/7 businesswire.com/news/home/2026…

Proceeds are expected to support topline Phase 2 data in second-line advanced endometrial cancer and initiation of a Phase 1b trial in first- and second-line HR+/HER2- advanced breast cancer, alongside completion of our ongoing Phase 1/2 trial of solnerstotug. ... 6/7

Today, Sensei Biotherapeutics announced the acquisition of Faeth Therapeutics. ... 1/7

Join @senseibio $SNSE for a virtual KOL event on Oct. 20 at 8am ET with Dr. Papadopoulos to discuss the unmet need in immunotherapy-resistant solid tumors, plans for Phase 2 studies, and data from the solnerstotug Phase 1/2 dose expansion cohort. Register: lifescievents.com/event/wuqpfn35…

Our President and CEO, @jcelebi, will join other industry leaders in a panel discussion at the Canaccord Genuity Horizons in Oncology Virtual Conference. Learn more here: investors.senseibio.com/news-releases/…

We’re excited to announce favorable preliminary data from the dose expansion portion of our Ph 1/2 trial evaluating, solnerstotug, our conditionally active VISTA-targeting antibody. Learn more about the results and how to access our upcoming webcast here: investors.senseibio.com/news-releases/…

#SensationalReview: VISTA Across Tumors. Studies have shown that VISTA is found in nearly all solid tumors with a high unmet need, which highlights the potential of VISTA targeting therapies for patients. Check out this publication to learn more: esmoopen.com/article/S2059-…

#SensationalReview: Targeting VISTA. Sensei is focused on developing conditionally active therapeutics that could selectively target immune checkpoints in a tumor and widen the therapeutic window. Learn more about our approach here: senseibio.com/approach/

We're excited to announce our new #SensationalReview Series, where we’ll dive into our origins, science, technology, and progress to date. Learn more about Sensei now here: senseibio.com

Today we provided a corporate update on our lead candidate, solnerstotug (SNS-101), and upcoming milestones. Read the full press release to learn more about what to look for in 2025 here: investors.senseibio.com/news-releases/… $SNSE

Sensei’s management team will participate in @Citi 2024 Global Healthcare Conference, being held in Miami, FL, on December 3-5, 2024. Learn more here: investors.senseibio.com/news-releases/… $SNSE

Today we reported our third quarter 2024 financial results and recent business highlights. To learn more about our progress and upcoming milestones, read the full press release here: investors.senseibio.com/news-releases/… $SNSE

We look forward to presenting at PEGS Europe: Protein and Antibody Engineering Summit and @sitcancer 39th Annual Meeting. For additional details read the full press release here: investors.senseibio.com/news-releases/… #PEGSEurope #SITC2024

This week, our Senior Director, Biologics Discovery & Early Development, Thomas Thisted PhD, presented an overview of our first conditionally active bispecific program, SNS-201, at the 15th Annual World Bispecific Summit. View the presentation here: investors.senseibio.com/events-present…

We’re excited to present preclinical data on our conditionally active SNS-103 program targeting CD39 at the upcoming CRI-ENCI Eighth International Cancer Immunotherapy Conference. More info here: investors.senseibio.com/news-releases/…

This month, $SNSE’s management will present at the @HCWCO 26th Annual Global Investment Conference and the @CantorFitzgerld Global Healthcare Conference. For additional details read the full press release: investors.senseibio.com/news-releases/…